文献速递颈动脉与弓上血管

慢性肾病患者可安全接受颈动脉内膜切除术与经颈动脉血管重建术

Carotid endarterectomy and transcarotid artery revascularization can be performed with acceptable morbidity and mortality in patients with chronic kidney disease.
PubMed 文献 · J Vasc Surg · 2024-04-20

基于血管质量倡议(VQI)2016至2021年数据,比较慢性肾病(CKD)患者接受颈动脉内膜切除术(CEA)、经股动脉颈动脉支架置入术(TFCAS)和经颈动脉血管重建术(TCAR)的30天结局。无症状患者卒中/死亡复合率CEA 1.4%、TCAR 1.2%、TFCAS 1.8%;有症状患者分别为2.7%、2.3%、3.7%。作者结论认为TFCAS不应在CKD患者中施行,若其解剖上适合TCAR或CEA。

要点

  • CKD患者中,无症状者卒中/死亡复合率CEA 1.4%、TCAR 1.2%、TFCAS 1.8%。
  • 有症状者卒中/死亡复合率CEA 2.7%、TCAR 2.3%、TFCAS 3.7%。
  • 作者结论:CKD患者若解剖上适合TCAR或CEA,不应施行TFCAS。

核心结论

  • CKD患者中,TCAR和CEA的无症状患者卒中/死亡复合率低于2%,有症状患者低于3%。
  • 鉴于主要并发症和死亡风险增加,CKD患者若解剖上适合TCAR或CEA,不应施行TFCAS。

研究设计与样本

  • 分析血管质量倡议(VQI)2016至2021年接受颈动脉血管重建(CEA、TFCAS、TCAR)的患者。
  • 排除肾功能正常(估算肾小球滤过率>90 mL/min/1.72 m2)者,无症状与有症状颈动脉狭窄分别评估。
  • 共纳入90,343例CKD患者:CEA 66,870例、TCAR 13,459例、TFCAS 10,014例;无症状63%、有症状37%。
  • 比较术前人口学、手术细节及30天死亡、卒中、心肌梗死(MI)和卒中/死亡复合结局,多变量分析校正组间差异包括CKD分期。

主要发现

  • 无症状患者30天卒中/死亡复合率:CEA 1.4%、TCAR 1.2%、TFCAS 1.8%;有症状患者:CEA 2.7%、TCAR 2.3%、TFCAS 3.7%。
  • 校正分析中,TCAR较CEA的30天死亡率更低(无症状:aOR 0.4,95%CI 0.3-0.7;有症状:aOR 0.5,95%CI 0.3-0.7),两症状队列中卒中、MI或卒中/死亡复合结局无差异。
  • TCAR较CEA的其他心脏并发症风险在无症状患者中更低(aOR 0.7,95%CI 0.6-0.9),有症状患者中风险相似。
  • TCAR较TFCAS的30天死亡率更低(无症状:aOR 0.5,95%CI 0.2-0.95;有症状:aOR 0.3,95%CI 0.2-0.4),有症状患者卒中更低(aOR 0.7,95%CI 0.5-0.97),卒中/死亡复合率更低(无症状:aOR 0.7,95%CI 0.5-0.97;有症状:aOR 0.6,95%CI 0.4-0.7),MI或其他心脏并发症无差异。
  • 有症状患者中,TFCAS较CEA的30天死亡率更高(aOR 1.8,95%CI 1.2-2.5)、卒中风险更高(aOR 1.3,95%CI 1.02-1.7),MI或其他心脏并发症无差异。

临床怎么用

  • 作者结论认为,CKD患者中TCAR和CEA的卒中/死亡复合率在无症状者低于2%、有症状者低于3%。
  • 作者结论认为,鉴于主要并发症和死亡风险增加,CKD患者若解剖上适合TCAR或CEA,不应施行TFCAS。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with chronic kidney disease (CKD) are considered a high-risk population, and the optimal approach to the treatment of carotid disease remains unclear. Thus, we compared outcomes following carotid revascularization for patients with CKD by operative approach of carotid endarterectomy (CEA), transfemoral carotid artery stenting (TFCAS), and transcarotid arterial revascularization (TCAR). METHODS: The Vascular Quality Initiative was analyzed for patients undergoing carotid revascularizations (CEA, TFCAS, and TCAR) from 2016 to 2021. Patients with normal renal function (estimated glomular filtration rate >90 mL/min/1.72 m2) were excluded. Asymptomatic and symptomatic carotid stenosis were assessed separately. Preoperative demographics, operative details, and outcomes of 30-day mortality, stroke, myocardial infarction (MI), and composite variable of stroke/death were compared. Multivariable analysis adjusted for differences in groups, including CKD stage. RESULTS: A total of 90,343 patients with CKD underwent revascularization (CEA, n = 66,870; TCAR, n = 13,459; and TFCAS, n = 10,014; asymptomatic, 63%; symptomatic, 37%). Composite 30-day mortality/stroke rates were: asymptomatic: CEA, 1.4%; TCAR, 1.2%; TFCAS, 1.8%; and symptomatic: CEA, 2.7%; TCAR, 2.3%; TFCAS, 3.7%. In adjusted analysis, TCAR had lower 30-day mortality compared with CEA (asymptomatic: adjusted odds ratio [aOR], 0.4; 95% confidence interval [CI], 0.3-0.7; symptomatic: aOR, 0.5; 95% CI, 0.3-0.7), and no difference in stroke, MI, or the composite outcome of stroke/death in both symptom cohorts. TCAR had lower risk of other cardiac complications compared with CEA in asymptomatic patients (aOR, 0.7; 95% CI, 0.6-0.9) and had similar risk in symptomatic patients. Compared with TFCAS, TCAR patients had lower 30-day mortality (asymptomatic: aOR, 0.5; 95% CI, 0.2-0.95; symptomatic: aOR, 0.3; 95% CI, 0.2-0.4), stroke (symptomatic: aOR, 0.7; 95% CI, 0.5-0.97), and stroke/death (asymptomatic: aOR, 0.7; 95% CI, 0.5-0.97; symptomatic: aOR, 0.6; 95% CI, 0.4-0.7), but no differences in MI or other cardiac complications. Patients treated with TFCAS had higher 30-day mortality (aOR, 1.8; 95% CI, 1.2-2.5) and stroke risk (aOR, 1.3; 95% CI, 1.02-1.7) in symptomatic patients compared with CEA. There were no differences in MI or other cardiac complications. CONCLUSIONS: Among patients with CKD, TCAR and CEA showed rates of stroke/death less than 2% for asymptomatic patients and less than 3% for symptomatic patients. Given the increased risk of major morbidity and mortality, TFCAS should not be performed in patients with CKD who are otherwise anatomic candidates for TCAR or CEA.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Elizaga N, Ghosh R, Saldana-Ruiz N, et al. Carotid endarterectomy and transcarotid artery revascularization can be performed with acceptable morbidity and mortality in patients with chronic kidney disease. J Vasc Surg. 2024. PMID: 38649102. doi:10.1016/j.jvs.2024.04.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。